Physician profile
Peter Umukoro
NPI 1679924013
$4,678.17
in general payments reported to CMS, 2019-2025
20 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2021: $28.04 · 2022: $214 · 2023: $702 · 2024: $1,090 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,532.11 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,207.64 | 2022-2025 | Farxiga |
| Amgen INC. | $386.44 | 2024-2025 | Krystexxa, Tavneos, Uplizna |
| Novartis Pharmaceuticals Corporation | $322.77 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $241.51 | 2022-2025 | |
| Lilly USA, LLC | $167.24 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $142.48 | 2024-2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $139.53 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $97.45 | 2023-2025 | |
| Ardelyx, INC. | $69.79 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $65.51 | 2025 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $60.66 | 2023-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.93 | 2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $38.76 | 2022-2023 | Lupkynis |
| Scpharmaceuticals INC. | $38.51 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $33.99 | 2023 | |
| Vifor Pharma, INC. | $28.04 | 2021 | |
| Apellis Pharmaceuticals, INC. | $23.29 | 2025 | Empaveli |
| Mallinckrodt Hospital Products INC. | $21.33 | 2025 | Acthar |
| Shield Therapeutics INC | $17.19 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Umukoro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.